Coronavirus, China rejects the anti-HIV drug

0
17


The use of the anti-combinationHiv Lopinavir/Ritonavir that many Italian hospitals are using to fight Covid19 infection in more serious adult patients is state rejected by China. According to a study of 199 people with Covid19, in the 28 days of therapy there were no significant benefits among the 99 patients undergoing therapy Lopinavir/Ritonavir in addition to standard care and the 100 patients who had standard care. In research coordinated by Professor Bin Cao of the China-Japan Friendship Hospital & Capital Medical University of Beijing and published in New England, it is concluded that “has not been observedor no benefit with Lopinavir/Ritonavir beyond standard care. In fact, reading in depth the study of the secondary benefits, albeit modest compared to the standard treatments alone, there were like a clinical improvement of 1 day less than the standard treatments. The 28-day mortality that the study considers similar, also treated for the anti-combination combinationHiv it drops by 5.8 percentage points, from 25 to 19.2%. The study started from the fact that in 2003, the Lopinavir had been approved to combat the SARS epidemic because it had given good results both in vitro and in combination with Ritonavir (which increases it its plasma half-life) on a group of patients in a study which, however, was not randomizzato. Subsequently the sthis combination had given good results on animals with MERS (Middle Eastern respiratory syndrome).

Even in this time of emergency, Republic is at the service of its readers.
To understand the changing world with verified news, investigations, updated data, without ever hiding anything from citizens
Carlo Verdelli
SUBSCRIBE TO REPUBLIC

# subscription-message{background-color:# f1f1f1;padding:48px 16px;display:block;margin:32px 0 16px;border-top:2px solid # f3bb02;border-bottom:2px solid # f3bb02;position:relative}# subscription-message p{font-family:georgia;font-style:italic;font-size:24px;line-height:30px;color:# 3c3c3c;margin-bottom:8px}.subscription-message_author{font-family:side;text-transform:uppercase;font-size:14px;text-align:right;display:block;margin-bottom:32px;margin-right:16px;font-weight:700}# subscription-message a{display:block;width:210px;padding:8px;color:#fff;border-bottom:none;background-color:# e84142;text-align:center;margin:0 auto;border-radius:3px;font-family:side,sans-serif;font-size:17px;line-height:24px;-webkit-box-shadow:0 0 20px 0 rgba (0,0,0,.6);–moz-box-shadow:0 0 20px 0 rgba (0,0,0,.6);box-shadow:0 0 20px 0 rgba (0,0,0,.6)}# subscription-message to:hover{background-color:# db1b1c;border-bottom:none;-webkit-box-shadow:0 0 0 0 rgba (0,0,0,.6);-moz-box-shadow:0 0 0 0 rgba (0,0,0,.6);box-shadow:0 0 0 0 rgba (0,0,0,.6)}

We are not a party, we do not seek consensus, we do not receive public funding, but we are standing thanks to the readers who buy us on newsstands every morning, look at our site or subscribe to Rep :.
If you are interested in continuing to listen to another bell, perhaps imperfect and some days irritating, continue to do it with conviction.
Mario Calabresi
Support journalism
Subscribe to Repubblica

->

->

LEAVE A REPLY

Please enter your comment!
Please enter your name here